William A Denny

List of Publications by Year in Descending Order

126 papers	8,322 citations	51 h-index	89 g-index
127 ext. papers	8,739 ext. citations	5.9 avg, IF	5.64 L-index

#	Paper	IF	Citations
126	Structures and dynamics of DNA complexes of the desmethyl analog of the cytotoxin MLN944: Insights into activity when a methyl isnR futile. *Journal of Molecular Recognition*, **2020**, 33, e2843	2.6	1
125	Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. *Journal of Medicinal Chemistry*, **2016**, 59, 8103-24	8.3	40
124	Inhibitors of the Phosphatidylinositol 3-Kinase Pathway **2014**, 449-478		2
123	The solution structure of bis(phenazine-1-carboxamide)-DNA complexes: MLN 944 binding corrected and extended. *Biopolymers*, **2014**, 101, 1099-113	2.2	3
122	Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. *Biochemical Pharmacology*, **2013**, 85, 1091-103	6	44
121	Structure-activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 3147-53	3.4	13
120	Therapeutic reactivation of mutant p53 protein by quinazoline derivatives. *Investigational New Drugs*, **2012**, 30, 2035-45	4.3	8
119	Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. *Science Translational Medicine*, **2011**, 3, 94ra70	17.5	350
118	Epigenetic regulation of gene expression as an anticancer drug target. *Current Cancer Drug Targets*, **2011**, 11, 199-212	2.8	35
117	Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs **2010**, 83-150		
116	4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. *Journal of Medicinal Chemistry*, **2010**, 53, 787-97	8.3	43
115	A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. *Cancer Research*, **2009**, 69, 4277-85	10.1	206
114	A new short synthesis of 5,6-dimethylxanthenone-4-acetic acid (ASA404, DMXAA). *Tetrahedron Letters*, **2009**, 50, 3945-3947	2	10
113	A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. *Cancer Cell*, **2008**, 14, 90-102	24.3	211
112	Non-covalent ligand/DNA interactions: minor groove binding agents. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2007**, 623, 24-40	3.3	134
111	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. *Journal of Medicinal Chemistry*, **2006**, 49, 1475-85	8.3	72
110	Hypoxia-activated anticancer drugs. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 635-646	6.8	15

109	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 1341-55	3.4	39
108	Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 3657-65	3.4	20
107	Structures of two minor-groove-binding quinolinium quaternary salts complexed with d(CGCGAATTCGCG)(2) at 1.6 and 1.8 Angstrom resolution. *Acta Crystallographica Section D: Biological Crystallography*, **2005**, 61, 1348-53		5
106	DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. *Journal of Medicinal Chemistry*, **2004**, 47, 475-88	8.3	57
105	Tumor-activated prodrugs--a new approach to cancer therapy. *Cancer Investigation*, **2004**, 22, 604-19	2.1	131
104	DNA and the chromosome - varied targets for chemotherapy. *Cell & Chromosome*, **2004**, 3, 2		36
103	Prospects for hypoxia-activated anticancer drugs. *Anti-Cancer Agents in Medicinal Chemistry*, **2004**, 4, 395-9		18
102	The Design of Drugs that Target Tumour Hypoxia. *Australian Journal of Chemistry*, **2004**, 57, 821	1.2	15
101	Dual topoisomerase I/II inhibitors in cancer therapy. *Current Topics in Medicinal Chemistry*, **2003**, 3, 339-53	3	120
100	Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). *Journal of Biomedicine and Biotechnology*, **2003**, 2003, 48-70		81
99	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. *Journal of Medicinal Chemistry*, **2003**, 46, 1049-54	8.3	47
98	Synthetic DNA-Targeted Chemotherapeutic Agents and Related Tumor-Activated Prodrugs **2003**, 51-105		2
97	Irreversible inhibitors of the erbB family of protein tyrosine kinases **2002**, 93, 253-61		30
96	Synthesis and evaluation of unsymmetrical bis(arylcarboxamides) designed as topoisomerase-targeted anticancer drugs. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 19-29	3.4	25
95	An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). *European Journal of Medicinal Chemistry*, **2002**, 37, 825-8	6.8	12
94	Synthesis and cytotoxicity of potential anticancer derivatives of pyrazolo[3,4,5-kl]acridine and indolo[2,3-a]acridine. *Tetrahedron*, **2002**, 58, 175-181	2.4	18
93	Acridine derivatives as chemotherapeutic agents. *Current Medicinal Chemistry*, **2002**, 9, 1655-65	4.3	234
92	THE CONTRIBUTION OF SYNTHETIC ORGANIC CHEMISTRY TO ANTICANCER DRUG DEVELOPMENT **2002**, 187-202		2

91	Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores. *Journal of Medicinal Chemistry*, **2002**, 45, 894-901	8.3	24
90	Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents. *Journal of Medicinal Chemistry*, **2002**, 45, 740-3	8.3	120
89	Nitroreductase-based GDEPT. *Current Pharmaceutical Design*, **2002**, 8, 1349-61	3.3	81
88	Positioning of the carboxamide side chain in 11-oxo-11H-indeno[1,2-b]quinolinecarboxamide anticancer agents: effects on cytotoxicity. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 445-52	3.4	51
87	Prodrug strategies in cancer therapy. *European Journal of Medicinal Chemistry*, **2001**, 36, 577-95	6.8	231
86	The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. *Il Farmaco*, **2001**, 56, 51-6		42
85	Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. *Journal of Medicinal Chemistry*, **2001**, 44, 1407-15	8.3	56
84	Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **2001**, 44, 429-40	8.3	85
83	Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. *Anti-Cancer Drugs*, **2001**, 12, 683-90	2.4	43
82	Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 1835-9	3.4	20
81	Synthesis of substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: evaluation of structure-activity relationships for cytotoxicity. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 2461-6	3.4	30
80	DNA targeted platinum complexes: synthesis, cytotoxicity and DNA interactions of cis-dichloroplatinum(II) complexes tethered to phenazine-1-carboxamides. *Journal of Inorganic Biochemistry*, **2000**, 81, 111-7	4.2	46
79	Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. *Biochemical Pharmacology*, **2000**, 60, 969-78	6	29
78	Acridinecarboxamide topoisomerase poisons: structural and kinetic studies of the DNA complexes of 5-substituted 9-amino-(N-(2-dimethylamino)ethyl)acridine-4-carboxamides. *Molecular Pharmacology*, **2000**, 58, 649-58	4.3	39
77	Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. *Journal of Medicinal Chemistry*, **2000**, 43, 1380-97	8.3	243
76	Guanine specific binding at a DNA junction formed by d[CG(5-BrU)ACG](2) with a topoisomerase poison in the presence of Co(2+) ions. *Biochemistry*, **2000**, 39, 15055-61	3.2	20
75	Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. *Journal of Medicinal Chemistry*, **2000**, 43, 1350-8	8.3	82
74	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1999**, 42, 1803-15	8.3	166

73	Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. *Journal of Medicinal Chemistry*, **1999**, 42, 2373-82	8.3	33
72	Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. *Journal of Medicinal Chemistry*, **1999**, 42, 2383-93	8.3	123
71	N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. *Journal of Medicinal Chemistry*, **1999**, 42, 346-55	8.3	29
70	Major groove binding and DNA-induced fit in the intercalation of a derivative of the mixed topoisomerase I/II poison N-(2-(dimethylamino)ethyl)acridine-4-carboxamide (DACA) into DNA: X-ray structure complexed to d(CG(5-BrU)ACG)2 at 1.3-A resolution. *Journal of Medicinal Chemistry*, **1999**, 42, 536-40	8.3	96
69	Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2. *Biochemistry*, **1999**, 38, 9221-33	3.2	82
68	Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues. *Biochemical Pharmacology*, **1998**, 56, 351-9	6	10
67	Quantitative structure-activity relationships (QSAR) for 9-anilinoacridines: a comparative analysis. *Chemico-Biological Interactions*, **1998**, 116, 157-80	5	14
66	Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. *Journal of Medicinal Chemistry*, **1998**, 41, 742-51	8.3	97
65	Inhibition of RNA synthesis in vitro by acridines--relation between structure and activity. *Zeitschrift Fur Naturforschung - Section C Journal of Biosciences*, **1998**, 53, 359-68	1.7	6
64	Dual topoisomerase I/II poisons as anticancer drugs. *Expert Opinion on Investigational Drugs*, **1997**, 6, 1845-51	5.9	35
63	Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. *Journal of Medicinal Chemistry*, **1997**, 40, 1919-29	8.3	65
62	Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. *Journal of Medicinal Chemistry*, **1997**, 40, 1270-5	8.3	60
61	Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. *Biochemical Pharmacology*, **1997**, 54, 877-87	6	62
60	Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1997**, 40, 3915-25	8.3	51
59	Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. *Journal of Medicinal Chemistry*, **1997**, 40, 1519-29	8.3	121
58	Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. *Journal of Medicinal Chemistry*, **1997**, 40, 2040-6	8.3	106
57	Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1997**, 40, 1820-6	8.3	90
56	Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. *Applied Radiation and Isotopes*, **1997**, 48, 487-92	1.7	8

55	A new synthesis of substituted acridine-4-carboxylic acids and the anticancer drug N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). *Tetrahedron Letters*, **1997**, 38, 699-702	2	21
54	Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. *Journal of Medicinal Chemistry*, **1996**, 39, 2508-17	8.3	33
53	Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. *Journal of Medicinal Chemistry*, **1996**, 39, 2518-28	8.3	37
52	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1996**, 39, 918-28	8.3	152
51	Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1996**, 39, 1823-35	8.3	120
50	Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1996**, 39, 267-76	8.3	286
49	Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. *Clinical and Experimental Pharmacology and Physiology*, **1996**, 23, 424-7	3	27
48	Radiolytic studies of the reductive cyclization of 2-nitroarylamides: Cyclization via hydroxylamine intermediates. *Journal of Physical Organic Chemistry*, **1995**, 8, 587-596	2.1	6
47	Anticancer drugs: an underestimated risk or an underutilised resource in mutagenesis?. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1995**, 331, 1-26	3.3	27
46	Interactions of acridine antitumor agents with DNA: binding energies and groove preferences. *Biochemistry*, **1995**, 34, 13682-7	3.2	57
45	Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1995**, 38, 3780-8	8.3	120
44	Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2Rdithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. *Journal of Medicinal Chemistry*, **1995**, 38, 58-67	8.3	66
43	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5Rtriphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. *Journal of Medicinal Chemistry*, **1995**, 38, 3482-7	8.3	235
42	Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. *Journal of Medicinal Chemistry*, **1995**, 38, 1928-41	8.3	23
41	Relationships between structure and kinetics of cyclization of 2-aminoaryl amides: potential prodrugs of cyclization-activated aromatic mustards. *Journal of Medicinal Chemistry*, **1994**, 37, 371-80	8.3	37
40	Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. *Journal of Medicinal Chemistry*, **1994**, 37, 381-91	8.3	55
39	Resonance Raman Study of the Binding of the Anticancer Drug Amsacrine to DNA. *Applied Spectroscopy*, **1994**, 48, 822-826	3.1	12
38	Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum. *Journal of Medicinal Chemistry*, **1994**, 37, 1486-94	8.3	92

37	Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. *Journal of Medicinal Chemistry*, **1994**, 37, 593-7	8.3	25
36	Acridine-based Anticancer Drugs **1994**, 270-311		12
35	Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. *Journal of Medicinal Chemistry*, **1993**, 36, 1839-46	8.3	169
34	Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. *Journal of Medicinal Chemistry*, **1992**, 35, 3214-22	8.3	66
33	Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. *Journal of Medicinal Chemistry*, **1992**, 35, 258-66	8.3	31
32	DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). *Journal of Medicinal Chemistry*, **1992**, 35, 2983-7	8.3	59
31	5-Nitro-4-(N,N-Dimethylaminopropylamino)quinoline (5-Nitraquine), a New DNA-Affinic Hypoxic Cell Radiosensitizer and Bioreductive Agent: Comparison with Nitracrine. *Radiation Research*, **1992**, 131, 257	3.1	12
30	Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 693-6	4	40
29	Surface-enhanced Raman spectroscopic study of amsacrine and amsacrine–DNA interactions. *Journal of Raman Spectroscopy*, **1992**, 23, 341-345	2.3	7
28	Damage of Egg Phosphatidylcholine Liposomes by DNA-Binding Cytotoxic Agents. *Bulletin of the Chemical Society of Japan*, **1991**, 64, 1364-1369	5.1	1
27	Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. *Journal of Medicinal Chemistry*, **1991**, 34, 217-22	8.3	172
26	Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. *Cancer Chemotherapy and Pharmacology* , **1991**, 28, 409-13	3.5	31
25	Lysis of egg phosphatidylcholine vesicles by tricyclic carboxamide antitumor agents. *Chemico-Biological Interactions*, **1990**, 75, 93-104	5	1
24	Structure-activity relationships for the mutagenic activity of tricyclic intercalating agents in Salmonella typhimurium. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1990**, 232, 233-41	3.3	10
23	Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. *Journal of Medicinal Chemistry*, **1990**, 33, 112-21	8.3	91
22	Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II. *Journal of Medicinal Chemistry*, **1990**, 33, 814-9	8.3	262
21	The interaction of substituted and rigidly linked diquinolines with DNA. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **1990**, 1048, 50-8		19
20	Kinetic and Equilibrium Binding Studies of a Series of Intercalating Agents That Bind by Threading a Sidechain through the DNA Helix. *Jerusalem Symposia on Quantum Chemistry and Biochemistry*, **1990**, 191-206		4

19	Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. *Journal of Medicinal Chemistry*, **1989**, 32, 23-30	8.3	58
18	Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. *Journal of Medicinal Chemistry*, **1989**, 32, 31-8	8.3	48
17	RPetiteRmutagenesis in Saccharomyces cerevisiae by a series of 2,7-di-alkyl-substituted derivatives of proflavine with differing DNA-binding properties. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1988**, 201, 213-8	3.3	3
16	Alkyl-linked diquinolines are monofunctional AT-selective DNA-intercalating agents. *FEBS Letters*, **1988**, 228, 235-40	3.8	7
15	Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. *Journal of Medicinal Chemistry*, **1987**, 30, 664-9	8.3	191
14	Reductive metabolism and hypoxia-selective toxicity of nitracrine. *International Journal of Radiation Oncology Biology Physics*, **1986**, 12, 1235-8	4	44
13	Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. *Journal of Medicinal Chemistry*, **1986**, 29, 879-87	8.3	118
12	Differences between central and peripheral rat alpha-adrenoceptors revealed using binuclear ligands. *European Journal of Pharmacology*, **1986**, 127, 27-35	5.3	10
11	NMR studies of the complex between the decadeoxynucleotide d-(GCATTAATGC)2 and a minor-groove-binding drug. *Biochemistry*, **1986**, 25, 5902-10	3.2	76
10	Interaction of paired homologous series of diacridines and triacridines with deoxyribonucleic acid. *Biophysical Chemistry*, **1985**, 22, 17-26	3.5	17
9	1H NMR study of the binding of Bis(acridines) to d(AT)5.d(AT)5. 1. Mode of binding. *Biochemistry*, **1985**, 24, 1441-9	3.2	36
8	1H NMR study of the binding of bis(acridines) to d(AT)5.d(AT)5. 2. Dynamic aspects. *Biochemistry*, **1985**, 24, 1449-60	3.2	30
7	Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics. *Journal of Medicinal Chemistry*, **1984**, 27, 450-65	8.3	259
6	Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. *Journal of Medicinal Chemistry*, **1981**, 24, 170-7	8.3	174
5	Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles. *Journal of Medicinal Chemistry*, **1979**, 22, 134-50	8.3	52
4	Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines. *Journal of Medicinal Chemistry*, **1978**, 21, 5-10	8.3	20
3	Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. *Journal of Medicinal Chemistry*, **1978**, 21, 658-68	8.3	182
2	Acridine-4-Carboxamides and the Concept of Minimal DNA Intercalators482-502		3

List of Publications